01222 WANG ON GROUP
- 0.043
- +0.008+22.86%
WANG ON GROUP News
WANG ON GROUP (01222.HK) and Wai Yuen Tong (00897.HK): Yuxun Investment plans to sell Hong Kong properties for HK$33 million
Gelonghui, May 3 | WANG ON GROUP (01222.HK) and Wai Yuen Tong (00897.HK) announced that on May 3, 2024, the seller Yuxun Investment Co., Ltd. (Wai Yuen Tong indirect wholly-owned subsidiary) entered into an interim agreement with the buyer (Insurance Company Limited) and the property agent (as a property agent). Based on this, the seller agreed to sell the property, and the buyer agreed to buy the property at a cost of HK$33 million.” “This property” refers to Shop B, G/F, Kwong Sing Building, 23-33 Shui Wo Street, Kowloon, Hong Kong. The property was purchased by the seller in 2005 and is currently being leased to be added
Hongan Group (01222) cancelled about 1,187 million shares on April 29
According to the Zhitong Finance App, Hongan Group (01222) announced the cancellation of approximately 1,187 million shares on April 29, 2024.
WANG ON GROUP (01222) received 1,187 million shares of the company distributed by Weiyuantang in physical distribution
According to Zhitong Finance App, WANG ON GROUP (01222) announced that it has received 1,187 million shares of Wang On Group Limited (Hongan Group Co., Ltd.) distributed by Wai Yuen Tong Medicine Holdings Limited (Wai Yuen Tong Pharmaceutical Holdings Co., Ltd.) in physical distribution.
Wai Yuen Tong Medicine Unit to Sell Properties in Hong Kong
Wai Yuen Tong Medicine Holdings (HKG:0897) unit Grand Quality Development has agreed to sell certain properties to a third-party buyer for HK$41 million. The properties consist of a shop and a flat in
Hongan Group (01222) has sold South China City Notes
According to Zhitong Finance App News, Hongan Group (01222) issued an announcement. I hereby refer to the joint announcement between the Company and Hongan Real Estate dated February 2, 2024. The content is related (including) to such previous sales matters. The Board of Directors announced that according to these current sales matters, the Group has sold these South China City Notes on the open market, with a total principal amount of approximately US$8.4 million (equivalent to approximately HK$65.7 million), and the total cost (excluding unpaid accrued interest) is approximately US$3.8 million (equivalent to approximately HK$29.4 million).
WANG ON GROUP (01222.HK) sold Huanan City Notes with a total principal amount of approximately US$8.4 million
GLONGHUI February 8 | WANG ON GROUP (01222.HK) ANNOUNCEMENT REGARDING (INCLUDING) SUCH PREVIOUS SALES. The board of directors announced that according to these current sales matters, the Group has sold these South China City Notes on the open market, with a total principal amount of about US$8.4 million, and the total cost (excluding unpaid accrued interest) is approximately US$3.8 million.
Hongan Real Estate (01243) subsidiary sales of Huanan City notes with a total principal amount of about 3 million US dollars
According to the Zhitong Finance App, WANG ON GROUP (01222) and Hongan Real Estate (01243) jointly announced that according to these current sales matters, the seller of Hongan Real Estate (a wholly-owned subsidiary of Hongan Real Estate) has sold these South China City notes on the open market from February 1, 2024 to February 2, 2024. The total principal amount is approximately US$3 million, and the total cost (excluding unpaid accrued interest) is approximately US$1.3 million.
Wai Yuen Tong Medicine Plans Special Dividend of Wang On, China Agri-Products Shares; Shares Up 7%
The board of Wai Yuen Tong Medicine Holdings (HKG:0897) recommended a special dividend through the distribution of shares in Wang On Group (HKG:1222) and China Agri-Products Exchange (HKG:0149). The m
Wai Yuen Tong to Buy Shop Space in Hong Kong
Wai Yuen Tong Medicine Holdings (HKG:0897) unit Sunbo Investment will sell a shop unit in Tsuen Wan, Hong Kong to Crown Mega for HK$38 million, a Monday filing said. The shop is still being rented out
宏安集團：二零二三年中期報告
Wai Yuen Tong Medicine to Extend Revolving Loan Facility to Wang On
Wai Yuen Tong Medicine Holdings (HKG:0897) unit Wai Yuen Tong Medicine will grant a revolving loan facility of up to HK$100 million to Wang On Group (HKG:1222) for a five-year term. The facility carri
Wai Yuen Tong (00897) subsidiaries grant revolving loan facilities of not more than HK$100 million to Hongan Group (01222)
Wai Yuen Tong (00897) announced that on December 18, 2023, the company has about 99.8% of the subsidiaries...
Wang On Group Returns to Profit in Fiscal H1
Wang On Group (HKG:1222) returned to a profit of HK$111 million, or HK$0.0081 per share, in the fiscal first half, from a loss of HK$23.6 million, or HK$0.0017 per share, in the year-ago period, a Wed
Hongan Group (01222) announced interim results, profit attributable to shareholders of HK$111 million
Hongan Group (01222) announced the results for the six months ended September 30, 2023, with total revenue of 1,136 billion yuan...
WANG ON GROUP: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Wai Yuen Tong (00897.HK) plans to sell all of Tung Wah Investment's shares for HK$100 million
Gelonghui November 21丨Wang ON GROUP (01222.HK) and Wai Yuen Tong (00897.HK) jointly announced that on November 21, 2023, the seller Guidepost Investments Limited (an indirect wholly-owned subsidiary of Wai Yuen Tong) and the guarantor entered into an interim agreement with the buyer Ascend Progress Limited and the property agent. According to this, the buyer conditionally agreed to sell all of the target company Donghua Investment Co., Ltd. Issuance of shares and transfer of sales loans
WANG ON GROUP (01222.HK) plans to hold a board meeting on November 28 to approve interim results
Gelonghui November 16丨WANG ON GROUP (01222.HK) announced that the company will hold a board meeting on November 28, 2023 (Tuesday) to consider and approve (including) the interim results of the company and its subsidiaries for the six months ended September 30, 2023, and consider the payment of interim dividends (if any).
Hongan Group's earnings forecast that equity holders of the parent company should account for no more than HK$130 million in profit in the medium term
Hongan Group (01222) announced that it expects the Group to obtain a profit attributable to parent company equity holders of no more than HK$130 million in the six months ending September 30, 2023, and losses attributable to parent company equity holders of about HK$23.6 million in the same period last year. According to the announcement, turning a loss into a profit was mainly due to the increase in the performance of the joint venture; and the increase in sales and gross profit from the production and sale of pharmaceuticals and health food, which was partly offset by a decrease in gross profit due to a reduction in delivery of property projects; and an increase in financing costs due to increased interest rates. This was compared with the same period in 2022 during the review period.
WANG ON GROUP (01222.HK) Profit: Expected medium-term net profit of no more than HK$130 million to turn a year-on-year loss into a profit
GLONGHUI November 13 - WANG ON GROUP (01222.HK) announced that the Group expects to record a shift from losses of about HK$23.6 million attributable to parent company equity holders in the 6 months ending September 30, 2022 to profits of less than HK$130 million due to parent company equity holders to profit for 6 months ending September 30, 2023. This was mainly due (among others) to (i) the increase in performance of joint ventures; and (ii) the increase in sales and gross profit from the production and sale of pharmaceuticals and health food, and partly due to (a) reduced delivery of property projects
Hongan Group (01222) is making a profit, predicting that equity holders of the parent company should account for no more than HK$130 million in profit in the medium term, turning a year-on-year loss into a profit
According to the Zhitong Finance App, Hongan Group (01222) announced that it expects the group to obtain a profit of no more than HK$130 million attributable to parent company equity holders in the six months ending September 30, 2023, and losses attributable to parent company equity holders of about HK$23.6 million in the same period last year.
Analysis
Price Target
No Data
